Sarah O Nomura1, Amy B Karger1, Natalie L Weir1, Daniel A Duprez2, Michael Y Tsai3. 1. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. 2. Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. 3. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. Electronic address: tsaix001@umn.edu.
Abstract
BACKGROUND: Fasting free fatty acid (FFA) levels may be associated with cardiovascular disease (CVD) and mortality, but research among generally healthy adults, females, and racially/ethnically diverse populations is lacking. OBJECTIVE: The primary aim of this project was to investigate prospective associations between fasting FFAs and coronary heart disease (CHD) and CVD incidence and CVD-specific and all-cause mortality in a generally healthy age, sex, and racially/ethnically heterogeneous population. METHODS: This study was conducted in the Multi-Ethnic Study of Atherosclerosis cohort using baseline (2000-2002) fasting FFAs and outcome data through 2015 (N = 6678). Cox proportional hazards regression was used to calculate hazard ratios for associations between FFAs and CHD, CVD, CVD-specific mortality, and all-cause mortality. Interactions by age, sex, race/ethnicity, and metabolic syndrome were evaluated by stratification and cross-product terms. A secondary analysis was conducted to evaluate associations between FFAs, and inflammatory and endothelial activation biomarkers were evaluated using linear regression (analytic N range: 964-6662). RESULTS: FFA levels were not associated with CHD or CVD incidence. Higher FFAs were associated with CVD-specific and all-cause mortality, but associations were attenuated in fully adjusted models with a borderline significant association remaining only for all-cause mortality (fully adjusted, per standard deviation increase hazard ratio = 1.07, 95% confidence interval: 1.00-1.14). Associations did not differ by age, sex, race/ethnicity, or metabolic syndrome. CONCLUSIONS: Fasting FFAs were not associated with CHD, CVD, or CVD-specific mortality and were modestly associated with all-cause mortality, regardless of age, sex, race/ethnicity, or metabolic syndrome status.
BACKGROUND: Fasting free fatty acid (FFA) levels may be associated with cardiovascular disease (CVD) and mortality, but research among generally healthy adults, females, and racially/ethnically diverse populations is lacking. OBJECTIVE: The primary aim of this project was to investigate prospective associations between fasting FFAs and coronary heart disease (CHD) and CVD incidence and CVD-specific and all-cause mortality in a generally healthy age, sex, and racially/ethnically heterogeneous population. METHODS: This study was conducted in the Multi-Ethnic Study of Atherosclerosis cohort using baseline (2000-2002) fasting FFAs and outcome data through 2015 (N = 6678). Cox proportional hazards regression was used to calculate hazard ratios for associations between FFAs and CHD, CVD, CVD-specific mortality, and all-cause mortality. Interactions by age, sex, race/ethnicity, and metabolic syndrome were evaluated by stratification and cross-product terms. A secondary analysis was conducted to evaluate associations between FFAs, and inflammatory and endothelial activation biomarkers were evaluated using linear regression (analytic N range: 964-6662). RESULTS: FFA levels were not associated with CHD or CVD incidence. Higher FFAs were associated with CVD-specific and all-cause mortality, but associations were attenuated in fully adjusted models with a borderline significant association remaining only for all-cause mortality (fully adjusted, per standard deviation increase hazard ratio = 1.07, 95% confidence interval: 1.00-1.14). Associations did not differ by age, sex, race/ethnicity, or metabolic syndrome. CONCLUSIONS: Fasting FFAs were not associated with CHD, CVD, or CVD-specific mortality and were modestly associated with all-cause mortality, regardless of age, sex, race/ethnicity, or metabolic syndrome status.
Authors: Zibo Xiong; Hong Xu; Xiaoyan Huang; Johan Ärnlöv; Abdul Rashid Qureshi; Tommy Cederholm; Per Sjögren; Bengt Lindholm; Ulf Risérus; Juan Jesús Carrero Journal: Clin J Am Soc Nephrol Date: 2015-01-30 Impact factor: 8.237
Authors: T Neunteufl; R Katzenschlager; A Hassan; U Klaar; S Schwarzacher; D Glogar; P Bauer; F Weidinger Journal: Atherosclerosis Date: 1997-02-28 Impact factor: 5.162
Authors: Stefan Pilz; Hubert Scharnagl; Beate Tiran; Ursula Seelhorst; Britta Wellnitz; Bernhard O Boehm; Jürgen R Schaefer; Winfried März Journal: J Clin Endocrinol Metab Date: 2006-04-04 Impact factor: 5.958
Authors: Tobias Pischon; Susan E Hankinson; Gökhan S Hotamisligil; Nader Rifai; Walter C Willett; Eric B Rimm Journal: Circulation Date: 2003-06-23 Impact factor: 29.690